- Home
- ALT vs PROK Comparison
ALT vs PROK Comparison
Compare ALT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALT | PROK |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 359.1M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ALT | PROK |
|---|---|---|
| Price | $3.05 | $1.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $17.67 | $7.40 |
| AVG Volume (30 Days) | ★ 3.1M | 817.9K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $41,000.00 | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 105.00 | ★ 1075.00 |
| 52 Week Low | $2.56 | $0.54 |
| 52 Week High | $7.73 | $7.13 |
Technical Indicators
Market Signals| Indicator | ALT | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 52.33 |
| Support Level | $2.87 | $1.73 |
| Resistance Level | $3.26 | $2.58 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 66.00 | 77.50 |
Price Performance
Historical ComparisonAbout ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.